Educational Webinars

Diagnostic and management dilemmas in pulmonary hypertension webinar series session 6: Group 5 pulmonary hypertension; the unanswered questions - 4 DECEMBER, 2024

Diagnostic and management dilemmas in pulmonary hypertension webinar series session 6: Group 5 pulmonary hypertension; the unanswered questions - 4 DECEMBER, 2024

To take part in this event, you must register in advance.

 

4 December, 2024
18:00-19:00 CET

 

Chairs: Prof. Robin Condliffe (Sheffield, United Kingdom), Dr. Esther Jeritza Nossent (Amsterdam, Netherlands), Prof. Olivier Sitbon (Le Kremlin-Bicêtre, France)
External expert: Prof. David Montani (Le Kremlin-Bicêtre, France)

 

Session 6 'Group 5 pulmonary hypertension; the unanswered questions' overview:

Learning objectives:

  • Understand the different forms of group 5 disease
  • Appreciate different possible nature of PH in these conditions (e.g. Sarcoidosis - granulomatous vasculopathy v lung disease v compression; Myeloproliferative disease - group 5 versus CTEPH. LCH. NFM.
  • Appreciate the evidence for optimal treatment in these groups

Topics:

  • Cases demonstrating uncertainty in patients with various forms of group 5 disease: Sarcoidosis - granulomatous vasculopathy v lung disease v compression. Myeloproliferative disease - group 5 versus CTEPH. LCH. NFM.

Overview: Diagnostic and management dilemmas in pulmonary hypertension webinar series

 

The webinar series "Diagnostic and management dilemmas in pulmonary hypertension" highlights current important challenges in the diagnostic work-up and management of patients with pulmonary hypertension (PH).

 

The recent 2022 ERS/ESC PH guidelines highlight a number of theses dilemmas including patients diagnosed with idiopathic pulmonary arterial hypertension (IPAH) in the presence of respiratory and cardiovascular comorbidities.

 

Other health issues facing society, such as the obesity pandemic, present unique challenges in characterising PH adequately in relation to technical issues at right heart catheterisation and the presence of associated comorbidities including alveolar hypoventilation. We believe that a webinar series focusing on forms of PH which present diagnostic and management dilemmas will be of significant interest.

Educational aims:

Current important challenges in the diagnostic work-up and management of patients with pulmonary hypertension (PH) will be explored using an interactive case-based approach. Speakers will present background data and illustrative cases which will then be further discussed by the chairs and external expert. Following the webinars, participants will have increased understanding regarding the diagnosis and management of more complex an rarer forms of PH.

Target audience:

Pulmonologists and cardiologists working in the field of pulmonary hypertension, pulmonary vascular diseases, but also in the general field of pulmonology and also pulmonologist and cardiologist in training.

Learning outcomes:

Following this webinar, participants will be able to:

  • Recognise important pitfalls in the diagnostic work-up of patients with pulmonary hypertension.
  • Use and understand the most appropriate imaging techniques in the diagnostic work-up of patients with pulmonary hypertension depending on the differential diagnosis.
  • Recognise the most prevalent congenital vascular abnormalities leading to pulmonary arterial hypertension.
  • Recognise the pitfalls and understand the important technical aspects when performing right heart catheterisation including in obese patients with pulmonary hypertension of different origin.
  • Appreciate diagnostic uncertainty in patients with PAH with cardiopulmonary comorbidities.
  • To recognise the right ventricle phenotype in post-capillary pulmonary hypertension.

Topics and schedule:

  • Session 1: PAH with cardiopulmonary comorbidities (7 February, 2024)
  • Session 2: Go with the flow: pulmonary hypertension with high cardiac output (3 April, 2024)
  • Session 3: Post-capillary pulmonary hypertension (5 June, 2024)
  • Session 4: CTEPH mimics (2 October, 2024)
  • Session 5: Obesity and pulmonary hypertension (6 November, 2024)
  • Session 6: Group 5 pulmonary hypertension; the unanswered questions (4 December, 2024)